Structuring, Negotiating and Managing Win/Win

Pharma and Biotech In-Licensing, Co-Development and Co-Promotion Agreements

Monday, November 14, 2005

About

Are you sure that your collaboration agreements adequately enhance your client's capabilities without giving away too much?

Collaboration among pharmaceutical manufacturers, biotech companies, and research universities has become commonplace, but the issues haven't gotten any less complex. In-licensing, co-development and co-promotion arrangements can offer great benefits in terms of asset exploitation and cost reduction, but they carry great risks as well.

These deals are often rife with potential misunderstandings and other minefields. In-house counsel, senior business executives and attorneys must understand all the potential legal and business pitfalls in depth while also taking into account the latest trends and changes so they can draft the agreements with full knowledge of the risks, before they are executed.

This American Conference Institute publication on Structuring, Negotiating and Managing Win/Win Pharma and Biotech In-Licensing, Co-Development and Co-Promotion Agreements will provide you with the strategies you need to overcome the challenges of creating successful alliances. You'll get the tools you need to negotiate and draft effective agreements that can endure the twists and turns that occur over the long course of product discovery and pipeline development.* The expert faculty of leading pharmaceutical and biotech counsel and executives provide valuable insights on:
  • The current and future outlook for industry collaborations and their financing
  • Maximizing the value of your current IP through alliances
  • Selecting the right partner and choosing a deal and governance structure that best suits your needs
  • Strategies for negotiating, structuring and drafting winning licensing, co-development and co-promotion agreements
  • Troubleshooting your collaborations and evaluating your options when the deal falters
  • The expanding opportunities for cross-border collaborations and their unique complexities


*American Conference Institute cannot guarantee that every presentation will be included in the publication.

Contents & Contributors

About

Are you sure that your collaboration agreements adequately enhance your client's capabilities without giving away too much?

Collaboration among pharmaceutical manufacturers, biotech companies, and research universities has become commonplace, but the issues haven't gotten any less complex. In-licensing, co-development and co-promotion arrangements can offer great benefits in terms of asset exploitation and cost reduction, but they carry great risks as well.

These deals are often rife with potential misunderstandings and other minefields. In-house counsel, senior business executives and attorneys must understand all the potential legal and business pitfalls in depth while also taking into account the latest trends and changes so they can draft the agreements with full knowledge of the risks, before they are executed.

This American Conference Institute publication on Structuring, Negotiating and Managing Win/Win Pharma and Biotech In-Licensing, Co-Development and Co-Promotion Agreements will provide you with the strategies you need to overcome the challenges of creating successful alliances. You'll get the tools you need to negotiate and draft effective agreements that can endure the twists and turns that occur over the long course of product discovery and pipeline development.* The expert faculty of leading pharmaceutical and biotech counsel and executives provide valuable insights on:
  • The current and future outlook for industry collaborations and their financing
  • Maximizing the value of your current IP through alliances
  • Selecting the right partner and choosing a deal and governance structure that best suits your needs
  • Strategies for negotiating, structuring and drafting winning licensing, co-development and co-promotion agreements
  • Troubleshooting your collaborations and evaluating your options when the deal falters
  • The expanding opportunities for cross-border collaborations and their unique complexities


*American Conference Institute cannot guarantee that every presentation will be included in the publication.

Contents & Contributors


PHARMA/BIOTECH COLLABORATIONS
John W. Gotto, Wyeth
Sue Washer, AGTC

MOVING FORWARD: THE DRIVES, THE DEALS AND THE LESSONS LEARNED
Hemmie Chang, Ropes & Gray

DESIGN AND ANALYSIS OF A PATENT PORTFOLIO
Ralph A. Loren, Palmer & Dodge

BUILD, BUY, LICENSE-IN, CO-DEVELOP?
Joel Rothstein Wolfson, Blank Rome LLP

STRUCTURING A LICENSE FOR A FUTURE ROYALTY FINANCING
Stephen Johnson, Kirkland & Ellis

FINDING THE FINANCING & STRUCTURING THE DEAL: THE INTERPLAY OF VENTURE CAPITAL AND LICENSING
Jonathan Lourie, Edwards Angell Palmer & Dodge, LLP

PAUL ROYALTY FUND OVERVIEW
Todd Davis, Paul Capital Partners

CHOOSING THE RIGHT PARTNER AND GOVERNANCE STRUCTURE FOR YOUR COLLABORATION
Alison J. Freeman-Gleason, Heller Ehrman, LLP

CREATING A SUCCESSFUL CO-PROMOTION COLLABORATION
Charles E. Yon, Coley Pharmaceutical Group, Inc.

CREATING A SUCCESSFUL CO-PROMOTION COLLABORATION: AVOIDING, MINIMIZING AND RESOLVING CONFLICTS
Philip M. Hahn, Pfizer Inc.

HANDLING FDA RELATED ISSUES IN DRAFTING YOUR COLLABORATION AGREEMENTS
Robert A. Dormer, Hyman, Phelps & McNamara, P.C.

WORKING FDA RELATED ISSUES INTO YOUR COLLABORATION AGREEMENTS
Gregory J. Glover, MD, JD, Ropes & Gray

WORKING FDA-RELATED ISSUES INTO YOUR COLLABORATION AGREEMENTS
Eric Rogers, Genentech

STRUCTURING "WIN-WIN" DEALS WITH UNIVERSITIES
Kathleen Denis, Rockefeller University
Gregory Ikonen, Arriva Pharmaceuticals
Joseph Yanchik, Tokai Pharmaceuticals

AVOIDING ANTITRUST PITFALLS IN IN-LICENSING, CO-DEVELOPMENT AND CO-PROMOTION
Lore Unt, Federal Trade Commission
David Hull, Covington & Burling
Stephen A. Stack, Dechert LLP

ONE MISSION, MANY COOPERATIVE WAYS: THE CROSS BORDER ASPECTS OF LICENSING, JOINT VENTURES AND OTHER COLLABORATIONS IN THE LIFE SCIENCES
Alan Jakimo, Sidley Austin Brown & Wood LLP
Mattias Adler, Cooley Godward LLP



DOCUMENT TYPES: PRESENTATIONS AVAILABLE: 0